48.12
+2.30%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sanofi ADR
Its shares trade under the ticker SNY. It has been listed since 1 July 2002. In the fiscal year to 31 December 2025, it reported revenue of $53.91bn and net income of $9.02bn. At that date it held total assets of $146.35bn and shareholders' equity of $82.37bn.
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 1 Jul 2002
- Employees
- 300,000
- Website
- sanofi.com ↗
- Head office
- 46 AVENUE DE LA GRANDE ARMEE, PARIS, I0, 75017
- Incorporated in
- I0
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sanofi ADR employs 300000 people globally to support its operations.
- The company markets vaccines for poliomyelitis and pertussis effectively.
- Sanofi collaborates with Exscientia on novel small-molecule oncology treatments.
Weaknesses
- The company is listed on the US market as an ADR.
- Sanofi operates from Paris while being incorporated in the US.
- Specific details on the Adagene Inc. agreement remain incomplete.
Opportunities
- Sanofi partners with ABL Bio to develop ABL301 for alpha-synucleinopathies.
- The firm uses the ATOMNET platform via Atomwise collaboration.
- Sanofi works with Kymera Therapeutics on IRAK4 protein degrader therapies.
Threats
- Sanofi faces competition in the rare diseases neurology segment.
- The company must manage complex collaborations with Innate Pharma SA.
- Developing hexavalent combination vaccines requires significant ongoing research investment.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.